|
|
Vaccine Detail
|
Adenovirus-mediated Human Interleukin-12 |
| Vaccine Information |
- Vaccine Name: Adenovirus-mediated Human Interleukin-12
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007208
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- IL12B
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Prostate-specific membrane antigen
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Human PBMCs were isolated on Histopaque 1077 gradients per the manufacturer’s protocol. PBMCs were washed twice with saline and stimulated with phytohemagglutinin-M (1.5% v/v) for 3 days in medium containing 10% fetal bovine serum. Cells were washed, counted, and incubated in 96 well round-bottomed plates (IFN-γ assays—100,000 cells/well; proliferation assays—12,500 cell/well) with increasing amounts of conditioned media from DU145 cells infected with Ad5-yCD/mutTKSR39rep-mIL12 (expressing mouse IL-12) or Ad5-yCD/mutTKSR39rep-hIL12 (expressing human IL-12) (Freytag et al., 2015).
- Description: A replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (Ad.hIL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the adenovirus selectively infects and replicates in tumor cells, which may result in tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma and inducing cytotoxic T cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. The safety of oncolytic adenovirus-mediated suicide and interleukin-12 (IL 12) gene therapy was evaluated in metastatic pancreatic cancer patients. (Barton et al., 2021; NCIT_C37515).
|
| Host Response |
|
|
| References |
Barton et al., 2021: Barton KN, Siddiqui F, Pompa R, Freytag SO, Khan G, Dobrosotskaya I, Ajlouni M, Zhang Y, Cheng J, Movsas B, Kwon D. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Molecular therapy oncolytics. 2021; 20; 94-9104. [PubMed: 33575474].
Freytag et al., 2015: Freytag SO, Zhang Y, Siddiqui F. Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer. Molecular therapy oncolytics. 2015; 2; . [PubMed: 26767191].
NCIT_C37515: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37515]
|
|
